glp-1 receptor agonists effects on cardiovascular risk reduction Impact of outcomes in heart failure with preserved ejection fraction (HFpEF): systematic review and meta-analysis | Clinical Research in Cardiology GLP-1 Receptor Agonists in Heart

Prespecified and post hoc analyses confirmed the consistent effects of dapagliflozin across kidney disease: improving global outcomes (KDIGO) risk categories [56,57]

Exenatide provides superior control over post-prandial hyperglycemia compared to conventional therapies due to its ability to mimic the effects of endogenous incretin hormones

For example, the LEADER trial showed that Liraglutide significantly reduced the risk of major adverse cardiovascular events (MACE) by 13% and cardiovascular death by 22% in comparison to placebo

Sensitivity analyses performed with a random effects model (MHOR 1.04, 95% CI [0.97, 1.11]) and excluding openlabel trials (MHOR 1.03, 95% CI [0.95, 1.10]) provided similar results